Combination chemotherapy with continuous L-asparaginase, lomustine, and prednisone for relapsed canine lymphoma

Journal of Veterinary Internal Medicine

Volumn 23, Issue 5, 2009, Pages 1058-1063

  Saba, C F ^a   Hafeman, S D ^b   Vail, D M ^a   Thamm, D H ^b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b Veterinary Dentistry and Oral Surgery   (United States)

Author keywords

Asparagine; CCNU; Dog; Lymphosarcoma; Rescue protocol

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; ASPARAGINASE; LOMUSTINE; PREDNISONE;

ANIMAL; ANIMAL DISEASE; ARTICLE; BLOOD; DOG; DOG DISEASE; ENZYMOLOGY; FEMALE; KAPLAN MEIER METHOD; LYMPHOMA; MALE; PATHOLOGY; THROMBOCYTE COUNT;

ALANINE TRANSAMINASE; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; DOG DISEASES; DOGS; FEMALE; KAPLAN-MEIERS ESTIMATE; LOMUSTINE; LYMPHOMA; MALE; PLATELET COUNT; PREDNISONE;

ANIMALIA; CANIS FAMILIARIS;

EID: 70349686612     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2009.0357.x     Document Type: Article

References (23)

1. Vail DM, Young KM. Canine lymphoma and lymphoid leukemias. In: Withrow SJ, Vail DM, eds. Withrow & MacEwen's Small Animal Clinical Oncology, 4th ed. St Louis, MO: Saunders Elsevier; 2007:699-733.
2. Bergman PJ, Ogilvie GK, Powers BE. Monoclonal antibody C219 immunohistochemistry against P-glycoprotein: Seqential analysis and predictive ability in dogs with lymphoma. J Vet Intern Med 1996;10:354-359.
3. Less JJ, Hughes CS, Fine RL, et al. P-glycoprotein expression in canine lymphoma: A relevant, intermediate model of multidrug resistance. Cancer 1996;77:1892-1898.
4. Moore AS, Leveille CR, Reimann KA, et al. The expression of P-glycoprotein in canine lymphoma and its association with multidrug resistance. Cancer Invest 1995;13:475-479.
5. Tew KD, Coluin OM, Jones RB. Clinical and high-dose alkylating agents. In: Chabner BA, Longo DL, eds. Cancer Chemotherapy and Biotherapy, 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2006:283-309.
6. Cole SPC, Tannock IF. Drug resistance. In: Tannok IF, Hill RP, Bristow RG, Harrington L, eds. The Basic Science of Oncology, 4th ed. New York: McGraw-Hill Medical Publishing Division; 2005:376-399.
7. Moore AS, London CA, Wood CA, et al. Lomustine (CCNU) for the treatment of resistant lymphoma in dogs. J Vet Intern Med 1999;13:395-398.
8. Rassnick KM, Mauldin GE, Al-Sarraf R, et al. MOPP chemotherapy for treatment of resistant lymphoma in dogs: A retrospective study of 117 cases (1989-2000). J Vet Intern Med 2002; 16:576-580.
9. Flory AB, Rassnick KM, Al-Sarraf R, et al. Combination of CCNU and DTIC chemotherapy for treatment of resistant lymphoma in dogs. J Vet Intern Med 2008;22:164-171.
10. Saba CF, Thamm DH, Vail DM. Combination chemotherapy with L-asparaginase, lomustine, and prednisone for relapsed or refractory lymphoma. J Vet Intern Med 2007;21:127-132.
11. Rogers KS. L-asparaginase for treatment of lymphoid neoplasia in dogs. J Am Vet Med Assoc 1989;194:1626-1630.
12. Garrett LD, Thamm DH, Chun R, et al. Evaluation of a 6month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med 2002;16:704-709.
13. Chabner BA, Friedmann AM. Asparaginase. In: Chabner BA, Longo DL, eds. Cancer Chemotherapy and Biotherapy, 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2006:476-483.
14. Copur MS, Rose MG, Chu E. Miscellaneous chemotherapeutic agents. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer, Principles & Practice of Oncology, 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005:416-422.
15. MacDonald VS, Thamm DH, Kurzman ID, et al. Does Lasparaginase influence efficacy or toxicity when added to a standard CHOP protocol for dogs with lymphoma? J Vet Intern Med 2005;19:732-736.
16. Jeffreys AB, Knapp DW, Carlton WW, et al. Influence of asparaginase on a combination chemotherapy protocol for canine multicentric lymphoma. J Am An Hosp Assoc 2005;41:221-226.
17. Veterinary Co-operative Oncology Group. Veterinary cooperative oncology group common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Compar Oncol 2004;2:194-213.
18. Chu E, DeVita VT. Principles of medical oncology. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer, Principles & Practice of Oncology, 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005:295-306.
19. Boyce KL, Kitchell BE. Treatment of canine lymphoma with COPLA/LVP. J Am Anim Hosp Assoc 2000;36:395-403.
20. Moore AS, Cotter SM, Rand WM, et al. Evaluation of a discontinuous treatment protocol (VELCAP-S) for canine lymphoma. J Vet Intern Med 2001;15:348-354.
21. Carter SK, Newman JW. Nitrosoureas: 1,3-bis (2-chloroethyl)1-nitrosourea (NSC-409962; BCNU) and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (NSC-79037; CCNU)-Clinical brochure. Cancer Chemother Rep (Part 3) 1968;1:115-151.
22. Rassnick KM, Moore AS, Williams LE, et al. Treatment of canine mast cell tumors with CCNU (lomustine). J Vet Intern Med 1999;13:601-605.
23. Kristal O, Rassnick KM, Gliatto JM, et al. Hepatotoxicity associated with CCNU (lomustine) chemotherapy in dogs. J Vet Intern Med 2004;18:75-80.